Cullen/Frost Bankers’s Denali Therapeutics DNLI Stock Holding History

Cullen/Frost Bankers’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257	Hold	10	–	–	﹤0.01%	1362
2026 Q1	$192	Buy	+10	New	+$199	﹤0.01%	1355

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cullen/Frost Bankers's DNLI Position: Q2 2026 in Review

Cullen/Frost Bankers held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 10 shares worth $257. The position accounts for ﹤0.01% of the portfolio, ranked #1362.

Cullen/Frost Bankers first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Cullen/Frost Bankers held 10 shares of Denali Therapeutics worth $257 as of Q2 2026.
Cullen/Frost Bankers left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1362 holding.
Cullen/Frost Bankers first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.